CVBT Licenses Phase II Diabetic Wound Healing Data From Merck

CardioVascular BioTherapeutics Inc. (Pink Sheets: CVBT) today announced the successful closing of an exclusive licensing agreement with an affiliate of Merck & Co., Inc., for clinical and scientific data regarding the therapeutic use of human fibroblast growth factor-1 (FGF-1) for the treatment of diabetic wounds, including Phase IIa and IIb data. CVBT intends to use the data, in conjunction with CVBT's own data, to apply to the FDA to advance its FGF-1 diabetic wound healing drug candidate, CVBT-141B, to a pivotal Phase III trial, which, if approved by the FDA, is anticipated to commence in 2011. Further, given the major unmet medical need to heal diabetic patients' open wounds, which are at great risk of infection and which once infected often lead to limb amputations, CVBT will be applying to the FDA for "Fast Track Development Program" status for CVBT-141B.

CVBT's CEO, Daniel C. Montano, stated that "the Phase II clinical data, in conjunction with additional unpublished pre-clinical data CVBT obtained in the licensing agreement, clearly support our belief that CVBT-141B is a promising wound-healing drug candidate, both in efficacy and safety. While CVBT is presently focused on seeking accelerated approval of CVBT-141B for diabetic wounds, CVBT is also planning to expand the use of this drug candidate to other wound healing indications including venous stasis ulcers, surgical wounds, and burns. Advanced wound management products, those used in the clinical management of wounds (not OTC), represents an estimated $5 billion global market opportunity that is predicted to triple in the next ten years. This is a large and growing medical marketplace opportunity for CVBT, which may at the same time save many lives and lessen the suffering of millions of diabetic patients."

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase III trial to treat dermal wound healing in diabetics (CVBT-141B) is planned to begin in 2011, pending FDA approval.

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.